Personalized treatment in advanced ALK-positive non-small cell lung cancer

From bench to clinical practice

Antonio Passaro, Chiara Lazzari, Niki Karachaliou, Gianluca Spitaleri, Alessia Pochesci, Chiara Catania, Rafael Rosell, Filippo de Marinis

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.

Original languageEnglish
Pages (from-to)6361-6376
Number of pages16
JournalOncoTargets and Therapy
Volume9
DOIs
Publication statusPublished - Oct 17 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Gene Rearrangement
Brain
anaplastic lymphoma kinase
Disease Progression
Neoplasm Metastasis
crizotinib

Keywords

  • Alectinib
  • ALK
  • Brain metastases
  • Brigatinib
  • Ceritinib
  • Crizotinib
  • Lorlatinib
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Personalized treatment in advanced ALK-positive non-small cell lung cancer : From bench to clinical practice. / Passaro, Antonio; Lazzari, Chiara; Karachaliou, Niki; Spitaleri, Gianluca; Pochesci, Alessia; Catania, Chiara; Rosell, Rafael; de Marinis, Filippo.

In: OncoTargets and Therapy, Vol. 9, 17.10.2016, p. 6361-6376.

Research output: Contribution to journalReview article

@article{99bab1288a1544f39bb78b4a93b261e3,
title = "Personalized treatment in advanced ALK-positive non-small cell lung cancer: From bench to clinical practice",
abstract = "The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-na{\"i}ve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.",
keywords = "Alectinib, ALK, Brain metastases, Brigatinib, Ceritinib, Crizotinib, Lorlatinib, NSCLC",
author = "Antonio Passaro and Chiara Lazzari and Niki Karachaliou and Gianluca Spitaleri and Alessia Pochesci and Chiara Catania and Rafael Rosell and {de Marinis}, Filippo",
year = "2016",
month = "10",
day = "17",
doi = "10.2147/OTT.S98347",
language = "English",
volume = "9",
pages = "6361--6376",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Personalized treatment in advanced ALK-positive non-small cell lung cancer

T2 - From bench to clinical practice

AU - Passaro, Antonio

AU - Lazzari, Chiara

AU - Karachaliou, Niki

AU - Spitaleri, Gianluca

AU - Pochesci, Alessia

AU - Catania, Chiara

AU - Rosell, Rafael

AU - de Marinis, Filippo

PY - 2016/10/17

Y1 - 2016/10/17

N2 - The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.

AB - The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second- or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naïve ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.

KW - Alectinib

KW - ALK

KW - Brain metastases

KW - Brigatinib

KW - Ceritinib

KW - Crizotinib

KW - Lorlatinib

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84991618953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991618953&partnerID=8YFLogxK

U2 - 10.2147/OTT.S98347

DO - 10.2147/OTT.S98347

M3 - Review article

VL - 9

SP - 6361

EP - 6376

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -